Europe: New Hemophilia A Medication Granted Orphan Status
December 4, 2014; Posted by: WeBleed staff
Apitope’s ATX-F8-117 given orphan designation from European Medicine Agency.
An article from Clinical Leader today announced that the pharmaceutical company, Apitope, was recently granted orphan drug status for its new hemophilia A drug. The European Medicine Agency approved Apitope’s ATX-F8-117, which is derived from Factor VIII and is being developed as a peptide therapy to prevent inhibitor development in hemophilia A patients treated with Factor VIII.
“We are very pleased to receive Orphan Medicinal Product Designation by the EMA for ATX-F8-117, which underlines the need for an effective treatment for patients with hemophilia A,” said Dr. Keith Martin, CEO of Apitope International, “ATX-F8-117 is currently in preclinical development for the treatment of Factor VIII inhibitors which develop in approximately 30 percent of patients and results in poor clotting leading to severe health issues for patients. More specifically, the potential impact of this product could be an important step in the fight to help hemophilia A patients who cannot benefit fully from Factor VIII replacement therapy.”
Apitope is a European biotech company focused on the discovery and development of revolutionary disease modifying therapies for autoimmune and allergic diseases, including multiple sclerosis, Graves’ disease, FVIII intolerance and uveitis.
Photo Credit – Apitope
webleed.org – your source for bleeding news!
